China’s SFDA Denies Illegal Exports Of Performance-Enhancing Drugs
This article was originally published in PharmAsia News
Executive Summary
Chinese regulators deny U.S. reports that China's bulk-drugs suppliers were illegally exporting performance-enhancing drugs to the United States. Wu Zhen, deputy head of the State FDA, said most of such shipments were clearly labeled and had company contracts, export licenses and "warrants from the importing countries." Wu said it was the responsibility of importing countries to police the illegal use of any legally imported drugs. China is emphasizing its own crackdown on use of steroids and other performance-enhancing drugs in advance of the summer Olympics. (Click here for more
You may also be interested in...
MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In
The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.
Medtronic Launches Remote Live-Stream Surgery, New AI Capabilities
Medtronic will launch a new feature that allows for live streaming of surgical procedures in more than 20 countries and the addition of 14 AI-driven algorithms to enhance surgical workflow.
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.